Biotech BD&L Tracker 2026

Dengue is a vaccine problem that vaccines have not solved — Dengvaxia’s serostatus restriction and Qdenga’s uneven serotype protection both left the same gap, which is what to give someone who is already infected or acutely exposed. A pan-serotype antibody is the therapeutic and short-term prophylactic answer, and GSK is the rare large pharma still building infectious disease capability at scale. The economics are pure royalty-plus-sublicensing with no disclosed upfront, which tells you Chugai valued getting the asset developed above monetising it now; for a Roche-group company with no tropical disease commercial footprint, that is the rational trade. Antibody cost of goods against a low-income-country epidemiology remains the unsolved commercial question.

The China-to-global out-licence template applied to biosimilars rather than novel assets. Sandoz is buying pipeline density ahead of the next wave of large-biologic patent expiries, and doing it without building ADC biosimilar capability itself — Henlius already has approved biosimilars in Europe and the manufacturing base to supply them. For Henlius it converts a development engine into recurring ex-China economics without funding a commercial build across eight jurisdictions. The number is modest against the novel-asset deals on this tracker, which is the point: biosimilar economics are supply-and-margin rather than milestone-driven, so US$322M understates the value if the platform delivers all 10.

Ion channels are the classic hard target for antibodies — multi-pass membrane proteins that resist conventional immunisation — and that difficulty is why a discovery-stage programme with no named target or indication carries a US$370M headline. For OmniAb, a platform company that has struggled to convert partnerships into visible economics, a Lilly signature at this size is the validation the equity story needed; the stock moved roughly 18% on the news. The caveat is that everything here is contingent: no disclosed upfront, no target, no indication, and milestone stacks on discovery deals convert at low single-digit rates. It is an option on Lilly’s conviction rather than a funded programme.

A clean, small monetisation that says more about Zealand’s capital allocation than about rusfertide. Zealand is converting a passive 1% interest in someone else’s commercial asset into cash it can put behind its own obesity and metabolic pipeline under the Metabolic Frontier 2030 strategy — the royalty was never going to be management’s focus. For Royalty Pharma it is a de-risked pre-approval buy with a PDUFA date weeks away, and the split above US$1.5B leaves Zealand upside if rusfertide becomes a genuine franchise. The retained sliver above a high threshold is becoming standard in royalty sales where the seller wants cash without giving up the blockbuster scenario entirely.

An option structure doing exactly what an option structure is for: Mereo, a small-cap already carrying setrusumab, gets a funded path into a Phase 3 it could not have run alone, and Sentynl gets a look at the design and CMC package before committing the US$40M. Alvelestat is the asset Mereo licensed from AstraZeneca in 2017 for US$5M upfront (US$3M cash plus new ordinary shares) with deferred milestones and royalties — a shelved-compound rescue that now carries a US$475M headline. AATD-LD still has no approved oral disease-modifying therapy and augmentation therapy is IV and lifelong, so a Phase 3 win would open a genuinely uncontested US label. The counterweight: nothing beyond the option fee is committed yet, and the option can lapse.

Innate has spent years looking for a partner willing to fund lacutamab through registration and found one that pays for the shot without taking the trial away — Innate keeps operational control of TELLOMAK-3 while Sobi carries the commercial burden. The US$75M at closing is material relative to Innate’s market cap and effectively resets its runway. For Sobi, KIR3DL2 is a clean rare-disease fit: Sézary syndrome is a few thousand patients globally with no targeted approved option, exactly the label profile Sobi commercialises well. The staged US$465M sits behind an option, so the real commitment today is US$115M.

The China-to-West template running in reverse. A US company hands Asian rights to a China-origin developer — and gets a globally-run registrational Phase 3 paid for in the bargain, which matters more than the undisclosed milestones. RevMed keeps Japan and South Korea, the two Asian markets with the pricing to justify holding, and gives away the ones that need local infrastructure it does not have. For BeOne it is access to the deepest RAS(ON) portfolio in the industry plus two combination partners of its own to differentiate on. Terms staying undisclosed is the tell that the economics run through trial funding rather than the biobucks.

The second enterprise-AI infrastructure deal on the tape inside a week, after ICON committed to deploying Anthropic’s Claude across clinical operations — and the pattern is now unmistakable: large pharma is buying model access and deployment engineers, not molecules. The London hub is the part with signal, siting Novo’s discovery AI effort in the UK rather than Denmark or Boston. The commercial extension into Amazon Pharmacy and One Medical is the quieter half of the announcement and arguably the more consequential one for a company whose obesity franchise is now fighting on access and distribution rather than efficacy.

A licensee buying out its own licensor before a registrational readout — the cleanest signal a partner can send about an asset. Oculis converts an uncertain, indication-by-indication royalty and milestone stack into a fixed price of US$3.8M plus equity, which matters most if privosegtor reads out across more than one optic neuropathy. The share-heavy consideration keeps cash intact and ties Accure to the outcome. Small money, high information content: watch for more licensees taking out royalty stacks ahead of pivotal data while the asset is still cheap to buy.

The mirror image of the trade that has defined 2026 — instead of a Chinese biotech out-licensing to the West, a Japanese pharma is renting a Chinese commercial platform. Daiichi has an approved drug in China and no efficient way to detail it into hematology centres; Innovent already carries sintilimab, rituximab and pirtobrutinib into the same accounts. No disclosed economics, which usually means a distribution-style margin split rather than a milestone package. Worth tracking as a category: as more Western and Japanese approvals land in China, in-country commercial infrastructure becomes the scarce asset.

A US$4.5B headline package retired for roughly US$28M, and the cleanest illustration yet of how little biobucks mean once a partner loses conviction. The read-through is not that sa-mRNA failed — Arcturus gets back a commercially approved vaccine and a stockpile-relevant H5N1 asset with no royalty stack on top — it is that CSL walked away from a marketed product rather than fund the commercial build, which is a statement about post-pandemic COVID vaccine economics. Arcturus now owns everything and funds everything, which is either the option value of the year or an unfunded liability, depending on whether it finds a second partner.

The second AstraZeneca-CSPC structure of 2026, after the up-to-US$18.5B discovery and licensing package that still tops the BD&L leaderboard — and this one moves from molecules to capacity. Onshoring biologics drug-substance manufacturing inside China with a domestic partner carrying most of the capital hedges AstraZeneca’s cost base at a moment when Section 232 tariffs, MFN pricing commitments and COINS Act scrutiny are all reshaping where product is made. For CSPC it is a route from out-licensor to manufacturing partner of record.

Odyssey listed in May 2026 on an oral RIPK2 inhibitor for ulcerative colitis and is now buying discovery throughput rather than building it, while Evotec continues to reposition from fee-for-service CRO toward risk-shared, AI-enabled partnership economics. The structure is becoming the default for newly public clinical-stage biotechs that need a second and third wave of programmes without a second and third wave of headcount.

A rights-reacquisition rather than an out-license — Actimed pulls back an asset it licensed away in 2021 and reunites S-oxprenolol (ACM-002) with lead candidate ACM-001 (S-pindolol) under one owner, broadening the indication set and presenting a cleaner, unencumbered global package to prospective partners or acquirers. In cancer cachexia, where no therapy is approved in the US and the commercial question is still unanswered, owning 100% of both ACTA assets is worth more at a negotiating table than a share of a split.

One of the largest CROs commits to a frontier-model vendor at the operations layer rather than running a pilot — the signal is that AI in clinical development is moving from discovery-side pitch decks into the cost base of running trials, where cycle time and monitoring headcount are the actual economics. It also puts pressure on IQVIA, Fortrea and Parexel to name their own model partners, and makes trial-operations software a contested layer rather than a settled one.

A CRO taking a development-partner role in cardiac gene therapy rather than a vendor role — heart-failure gene therapy has been slow to generate clean clinical packages, and pairing it with human-based discovery models is an explicit bet that translational failure, not manufacturing, is the bottleneck. If the structure carries risk-sharing economics, it is another data point that service providers are moving up the value chain into programme ownership.

A US$125M cash upfront written by a private company that was still marketing its own round the same evening — the deal and the fundraise were announced together because the deals are the pitch. JSKN016 enters the TROP2 fight against Merck/Kelun’s sac-TMT and AstraZeneca/Daiichi’s Dato-DXd on a bispecific angle rather than a payload one, which is a differentiated but unproven axis. Risk sits in COINS Act exposure on a China-sourced ADC and in whether the ~US$3B valuation the round is being marketed at actually clears.

AstraZeneca licensing an asset to a company it already co-funds through the Tempus foundation-model partnership is the tell: this is outsourced early development, with AZ retaining co-exclusive rights and Pathos carrying the clinical spend and the AI-driven patient-selection thesis. AZD4241 buys Pathos a shot at the oral degrader field where Menarini’s Orserdu and AZ’s own camizestrant already sit — a crowded target where the differentiation has to come from either degradation depth or patient selection.

A China-origin PARP inhibitor gets a European commercial partner with a filing already in front of the EMA — the cleanest version of the China-to-West template, where the originator sells geography rather than the molecule and keeps domestic economics. Mid-twenties royalties are unusually rich for a regional license and reflect how close the asset is to approval; the question is whether senaparib can find share in a European PARP market already served by Lynparza, Zejula and Rubraca.

The binding constraint on incretin revenue has been pens, not molecules, and Lilly is buying its way out of it with a domestic partner — which also lines up neatly with the MFN-plus-onshoring template that has deferred or zeroed out Section 232 pharma tariffs for signatories through 2029. For Resilience, a company that spent its first years searching for a durable business model, an anchor commitment of this size from the largest incretin franchise is the validation event.

Big pharma is now paying nine figures for training data rather than for molecules — an explicit statement that the scarce input in AI-enabled discovery is high-quality, purpose-generated biological data, not model architecture. It sets a public reference price for a data-only license and gives platform companies a monetisation route that does not require them to run their own clinical programmes.

A small but instructive print: Japan-only FcRn rights clear at US$5M upfront and US$27M total, which sets a floor comp for single-territory autoimmune licensing well below the global packages the class has been fetching. FcRn is a validated but increasingly crowded mechanism — argenx’s Vyvgart, J&J’s Imaavy and UCB’s Rystiggo are all commercial — so the value in a next-generation entrant now sits in dosing and route rather than in the target.

One of the biggest cell-therapy players buys a front-row seat in in vivo CAR-T — therapies generated directly inside the body rather than manufactured ex vivo — aimed at immune reset in autoimmune disease. The option-to-acquire structure lets J&J fund and validate Sail’s platform before committing the full US$2.58B, and slots alongside its Carvykti / Legend CAR-T franchise as the in vivo race (Lilly, AbbVie and others) heats up.

A non-dilutive royalty monetization that hands Neurimmune upfront cash while giving Royalty Pharma exposure to the large, competitive ATTR amyloidosis market. Reflects continued appetite for synthetic royalty deals on de-risked, big-pharma-partnered assets.

The out-license validates Mission’s USP30 platform and lets the company sharpen its focus on CNS, while giving ASX-listed renal specialist Dimerix a Phase 2-ready acute kidney injury asset. It is a capital-efficient, milestone-heavy structure typical of 2026 dealmaking, where modest upfronts fund refocusing without dilution.

A clean carve-out that lets the acquirer monetize non-core Kira assets while giving precision-medicine developer Mirador additional immuno-fibrotic shots on goal. Shows how bolt-on M&A is increasingly paired with simultaneous asset out-licensing.

A marquee China→West out-license paired with a reverse-merger listing and a US$320M raise — the “trifecta” structure that carries a China-originated oral inflammation asset into Western markets while the originator retains domestic economics. Signals continued appetite for oral IL-23 as a differentiated challenger to injectable biologics.

A tail-asset divestment that offloads a shelved antibiotic to a well-funded new entrant, letting Summit concentrate on its ivonescimab franchise. Illustrates opportunistic interest in resurrecting stranded anti-infective assets.

AstraZeneca in-licenses global rights to an already-approved oral EGFR exon20 drug from its own former spinout Dizal, deepening a lung-cancer franchise and adding a near-commercial, first-line-positioned asset. Another marquee China-origin oncology drug going global, and a rare example of a fully approved product changing hands via license.

Extends the China-to-global out-license template into autoimmune biologics: Innovent monetizes ex-China rights and retains domestic economics, while Spero pivots toward a differentiated Phase 2-ready immunology asset in a validated anti-CD40L class. Notable that a US biotech is the licensee taking a China-originated antibody global.

Reinforces the AI-discovery-to-China-commercial model and validates Insilico’s platform through repeat dealmaking with a single commercial partner. The milestone-heavy economics typify how AI-native discovery is being financed in 2026.

A high-value biosimilar out-license that expands Teva’s biosimilars pipeline under its “Pivot to Growth” strategy and takes aim at Roche’s multibillion-dollar Ocrevus MS franchise. It underscores continued dealmaking around biosimilars of large-molecule blockbusters as originator biologics move toward eventual loss of exclusivity.

Extends Teva’s biosimilar commercialization footprint in Canada into ophthalmology and adds to the intensifying anti-VEGF biosimilar competition against Regeneron/Bayer’s Eylea. A smaller, single-market commercialization deal, but a clean signal of continued biosimilar partnering across therapeutic areas.

A high-signal China-to-global respiratory license and one of the more meaningful 2026 non-oncology BD&L deals. AstraZeneca is paying a sizeable upfront for a differentiated inhaled PDE3/4 COPD asset with Chinese Phase 2/3 clinical validation, extending the China-origin out-license pattern beyond oncology, obesity and renal RNAi into respiratory disease.

A commercial-stage China respiratory rights deal rather than a pipeline license, but relevant for the tracker because it expands the GSK / Sino Biopharmaceutical alliance and shows global pharma using local partners to unlock China uptake for established specialty respiratory brands. It also pairs thematically with AstraZeneca's separate TQC3721 license from the same Chinese group on the same tape.

A smaller but clean oncology discovery BD&L add. The deal validates Astex's fragment-based discovery engine in a named breast-cancer biology programme and shows Roche / Genentech continuing to externalize early oncology target access even as many 2026 headline deals cluster around China-origin clinical assets and platform-scale collaborations.

Another high-signal China-to-global RNAi / kidney-disease transaction and a continuation of AstraZeneca's broader CSPC relationship after the companies' large obesity collaboration. The deal is modest upfront but sizeable in potential value, reinforcing pharma interest in China-origin RNA medicines and renal disease biology beyond classic small-molecule or antibody licensing.

A fresh AI-enabled discovery collaboration from Insilico shortly after its SK Biopharmaceuticals deal, showing continued pharma appetite for end-to-end target-to-candidate platforms. The economics are lower than the largest AI mega-collaborations, but the Takeda validation adds another quality datapoint for AI-native discovery partnerships moving beyond pilots into program-bearing BD&L structures.

A sizeable but heavily back-ended CNS out-license that gives AlzeCure a second 2026 Alzheimer's-related BD&L datapoint after the Lilly Alzstatin deal. The transaction is worth tracking because it shows continued appetite for non-amyloid / cognition-oriented Alzheimer's mechanisms, although the low upfront means the headline value should be interpreted cautiously.

A regional China immunology license rather than a global out-license, but still a useful BD&L datapoint given the sizeable upfront and competitive psoriasis market. The deal highlights local strategic appetite for IL-17 biology and gives Fosun a China-market biologic contender in a category dominated globally by Lilly, Novartis, UCB and other large immunology players.

A notable autoimmune T-cell-engager license that broadens the 2026 TCE tape beyond oncology. The deal combines a large back-ended milestone package with Deerfield-backed execution and supports the emerging thesis that T-cell-engaging formats may be repurposed for immune-cell depletion or immune reset in autoimmune disease, provided safety and therapeutic-index issues can be managed.

A material China-origin oncology TCE out-license that fits the 2026 China-to-global BD&L pattern but in preclinical solid-tumour T-cell engagers rather than ADCs or later-stage clinical assets. The structure pairs a sizeable milestone package with MPM BioImpact-backed NewCo execution, giving Antengene ex-Greater China monetization while retaining domestic rights and adding another datapoint for continuing buyer appetite around next-generation bispecific TCE formats.

A focused rare-disease commercialization deal around a near-approval antisense neurology asset. The economics are modest versus 2026 mega-deals, but the structure is publication-worthy because it gives Ionis a specialist ex-U.S. partner for FUS-ALS while preserving U.S. upside, and reinforces Recordati's rare-disease commercial strategy.

A must-add China-origin discovery collaboration that extends Lilly's 2026 run of external-innovation deals. The transaction is heavily back-ended, but the ~$1.9B potential value and multi-target structure make it a clean BD&L datapoint for pharma appetite around China-origin discovery engines beyond named clinical assets.

A must-add discovery-stage oncology collaboration with unusually meaningful upfront economics for a platform / early-program deal. The transaction reinforces Novartis' appetite for hard-to-drug oncology biology and sits alongside other 2026 platform collaborations where pharma is paying sizable upfront cash for differentiated target-access engines rather than only named clinical assets.

A BD&L-relevant NewCo formation rather than a classic asset license. The structure gives Merck early strategic control over a rare genetic cardiomyopathy platform while using Versant's company-building model to generate preclinical proof points before a potential acquisition, making it a useful 2026 datapoint for build-to-buy and option-style external innovation structures.

A publication-worthy China-to-global clinical-asset license that effectively transforms Nuvectis from an early oncology company into a broader late-stage developer spanning complement disease and oncology. The most notable asset is NXP100, already filed in China for PNH and in later-stage kidney-disease development, making this a more mature ex-China license than many discovery-heavy 2026 transactions.

A large back-ended AI drug-discovery collaboration that adds CNS / neuroimmune biology to the 2026 AI-enabled BD&L tape. The deal is strategically notable because SK Biopharmaceuticals is using Insilico's target-to-candidate engine to expand beyond epilepsy and cenobamate into broader neuroimmune CNS disorders, while Insilico adds another sizeable pharma-style collaboration shortly after its Lilly deal.

A smaller and less economically transparent platform option deal, but strategically relevant because it adds another AI/ML-enabled antibody-design collaboration focused on tumour-selective multispecifics. It fits the 2026 BD&L pattern of pharma and pharma-adjacent buyers using discovery partnerships to access engineered antibody formats that may improve therapeutic index in solid tumours.

A clean oncology multispecifics platform deal with meaningful disclosed upfront economics and large per-program option value. The collaboration gives Jazz access to AbCellera's T-cell engager discovery engine as Jazz expands around GI cancers and solid tumors, while reinforcing continued strategic appetite for next-generation TCEs despite therapeutic-index challenges in solid tumour immunotherapy.

A clean AI / biologics platform BD&L add that fits the 2026 pattern of large pharma paying for discovery engines rather than only named clinical assets. The deal is smaller than the headline AI mega-collaborations, but it is strategically relevant because Protillion is applying megascale protein data and AI design directly to biologics discovery, reinforcing the shift from software pilots toward platform licenses embedded in pharma R&D workflows.

A high-value genetic-medicine BD&L deal disclosed alongside the Boundless / Serapha reverse-merger and $230M financing. It adds a China-origin in vivo base-editing asset to the 2026 China-to-global pattern, but in rare disease rather than oncology or immunology, and shows that clinically supported gene-editing programs can anchor new public-company formation as well as classic out-licensing economics.

A must-add platform BD&L deal and a second Novartis collaboration for Orionis, reinforcing pharma appetite for rational molecular-glue discovery and hard-to-drug target access. The upfront is moderate, but the ~$1.4B milestone stack and repeat-partner signal put it squarely in the tracked 2026 platform-deal set alongside other targeted-protein-degradation and AI-enabled discovery collaborations.

A heavily back-ended but high-signal Alzheimer's BD&L deal that gives Lilly another oral small-molecule approach alongside its anti-amyloid franchise. ACD680 is designed to modulate gamma-secretase biology by reducing harmful Aβ42 production while increasing shorter benign Aβ peptides, giving Lilly optionality around plaque re-accumulation and potentially earlier or preventive Alzheimer's treatment strategies.

A major late-stage targeted-protein-degradation BD&L deal with unusually high upfront cash and meaningful retained economics for Nurix. Roche is buying into a potential best-in-class BTK degrader just ahead of Phase 3, with the strategic angle spanning CLL and other B-cell malignancies plus optionality in immunology and neurology where BTK biology remains highly partnerable.

A useful UK-origin platform BD&L deal in fibrosis, and strategically relevant for GSK's respiratory / immunology / inflammation and hepatology ambitions. The collaboration is not a named clinical-asset license, but it is worth tracking because it targets fibrosis regression — a historically difficult biology — and gives GSK optionality around human-tissue-derived targets rather than conventional preclinical screens.

A notable AI-platform deployment rather than a named therapeutic-asset license. The read-through is that large pharma is moving beyond external AI pilots toward embedded, proprietary-data-trained models that can sit inside biologics discovery workflows and potentially accelerate antibody, multispecific, or hard-target discovery programs.

A smaller regional license, but relevant because it extends Everest's autoimmune-nephrology footprint immediately after the Travere civorebrutinib deal. Bejescin is an anti-CD20 antibody approved in China for primary membranous nephropathy, and the transaction gives Everest APAC commercialization optionality around a de-risked biologic in a specialist kidney-disease market.

A material expansion rather than a brand-new collaboration, but worth tracking because Regeneron is putting additional cash behind conditional bispecific biology and taking the potential value of the CytomX pact to platform scale. It also reinforces renewed strategic interest in masked / conditionally activated oncology biologics as buyers try to widen therapeutic index for potent immune-engaging formats.

A high-signal RNAi platform deal combining Alnylam's siRNA leadership with Inceptive's AI-native RNA design engine. The structure fits the broader 2026 theme of pharma and RNA leaders paying for AI-enabled discovery tools that could improve potency, durability, developability, or target throughput rather than only licensing named clinical assets.

A must-add genetic medicines deal: Lilly is extending its external-innovation push into RNA exon editing and kidney disease, an area already showing strong 2026 BD&L momentum. For Ascidian, the deal validates a differentiated RNA-editing approach that could avoid permanent DNA edits while potentially addressing large genes or mutation classes that are difficult for conventional gene editing.

A sizeable nephrology BD&L deal that gives Travere a potential next-wave rare kidney disease asset beyond FILSPARI while letting Everest monetize ex-Asia rights to a BTK inhibitor with best-in-class positioning claims. The structure fits the broader 2026 China-to-global template: meaningful upfront cash, large indication-based milestone stack, and Asia rights retained by the originator.

Another high-signal China-to-global BD&L transaction from Lilly, following its broader 2026 run of external-innovation deals. The economics are heavily milestone-weighted, but the scale of the package shows Lilly continuing to use Chinese-origin discovery as a source of multi-program pipeline optionality across therapeutic areas.

A focused rare-hematology pipeline bolt-on for Agios that adds an oral SYK inhibitor in ITP while keeping near-term economics relatively disciplined. The Phase 2 data were not a clean statistical win, but Agios is underwriting durable platelet-response signals and specialist commercial fit rather than a broad-market immunology opportunity.

A strategically interesting expansion of Lilly's GLP franchise beyond obesity and diabetes into GI / intestinal-failure biology. The asset is a long-acting GLP-2 analog in Phase 2 for short bowel syndrome, where Hanmi is positioning potential lower treatment burden versus daily GLP-2 therapy; for Lilly, the deal adds a rare-disease/GI shot on goal with modest upfront risk but meaningful milestone torque.

A major ASCO-week China-to-global oncology collaboration and one of 2026's largest BD&L packages. Pfizer is effectively buying a broad option set across ADCs and multi-specific antibodies while Innovent monetizes its discovery engine with a large upfront, milestone torque, royalties, and selective co-commercialization economics — reinforcing that Western pharma continues to pay premium strategic prices for China-origin oncology innovation despite the live regulatory/political overhang around China-sourced biotech structures.

A meaningful commercial-stage regional out-license that lets Hansa monetize European/MENA rights while concentrating capital and execution on the U.S. opportunity ahead of a potential approval decision. The deal also shows specialist pharma appetite for transplant/rare immunology assets with established but still underpenetrated commercial footprints.

A high-signal platform deal that blends Regeneron's antibody engine with Parabilis' Helicon peptide technology to create antibody-Helicon conjugates. The investor read-through is that intracellular-target delivery remains one of the hottest BD bottlenecks: pharma will pay platform-scale economics where conjugation or cell-penetrant technology could unlock historically inaccessible biology.

A smaller but relevant platform-validation deal. The key read-through is not the upfront — undisclosed and subject to definitive agreement — but that targeted oligonucleotide delivery remains partnerable, especially where antibody-based tissue targeting could solve delivery bottlenecks for genetic-medicine or conjugated-oligo approaches.

Not a therapeutic asset license, but a relevant pharma-BD datapoint because it shows agentic AI moving from pilots into enterprise licensing. The read-through is that pharma is starting to pay for AI systems embedded into R&D and competitive-intelligence decision workflows, not just discovery-stage target or molecule generation.

A late-stage CNS option deal with meaningful cash economics ahead of a pivotal Alzheimer's readout. The structure gives Fosun global optionality without fully committing before POLARIS-AD reads out, while AriBio brings in non-dilutive capital and preserves upside if Phase 3 data are positive.

One of the largest disclosed BD&L packages of 2026. BMS is using a broad, risk-sharing portfolio structure to access Hengrui's early innovation engine across three priority disease areas, rather than betting on a single named late-stage asset.

A notable late-stage oncology handoff: Arvinas and Pfizer monetize and de-risk VEPPANU while preserving meaningful royalties, while Rigel gets a near-commercial breast cancer asset that could materially reshape its revenue profile if uptake follows the ESR1-mutant opportunity.

A clean early immunology license reinforcing the continued bid for preclinical antibody assets when the biology is differentiated. For Immunitas, it provides non-dilutive validation and economics while shifting global development risk to a large immunology-focused pharma buyer.

A useful platform read-through for oncology drug delivery: this is Halozyme's first ENHANZE deal explicitly including ADC targets, suggesting large pharma is looking for formulation and convenience advantages even in complex oncology modalities.

Another validation point for the "less frequent, lower-burden biologics" thesis in immunology: Oruka's clinical story is already about durable disease control, and delivery technology could become part of the product-profile differentiation.

A clean China-to-West oligonucleotide deal in cardiometabolic disease — and not a me-too GLP-1 story. The ALK7 angle gives GSK a differentiated route into obesity-adjacent metabolic risk, with a structure that preserves SiranBio's Greater China optionality while handing global scale-up to pharma.

Strategically logical bolt-on for Madrigal: adds a genetically defined RNAi program to the MASH leader's pipeline and gives Arrowhead non-dilutive economics while keeping the program in the hands of a hepatology-focused commercial owner.

A meaningful pipeline-broadening move for Cue into allergic disease, with ex-Greater China rights to a Phase 2 dual-mechanism anti-IgE. The $15M upfront against $676.5M in milestones (~45x ratio) is also a useful data point on how far back-ended deals around mid-stage Chinese assets have become.

A rights-consolidation deal rather than a fresh discovery bet: Biogen pays to simplify global ownership of felzartamab as it builds around immunology and plasma-cell biology. The $100M upfront for a regional carve-out is also another useful marker for how much strategic buyers will pay to remove territorial friction around priority assets.

A tidy regional monetisation for a chronic HBV program: Aligos brings in non-dilutive capital while keeping the higher-value Western and Japan/South Korea rights. Also shows that China regional partners remain willing to fund development around antiviral assets, not just oncology or immunology programs.

Another example of AbbVie paying for ex-China optionality in pain and neuroscience. The portfolio-style structure is notable — broader ex-China read-through beyond a single named program, which widens Haisco's global partnering signal.

Useful validation that large-cap pharma still sees targeted protein degradation as a platform worth expanding into. The modest upfront but very large back-end also fits the current risk-sharing template for platform collaborations.

A smaller regional obesity deal, but useful as another sign that China-origin incretin assets are being monetized outside China beyond the headline mega-deals. The economics are modest, but South Korea rights for a differentiated long-acting GLP-1 add another datapoint for regional commercial appetite in obesity/metabolic disease.

Not a fresh asset license, but a meaningful amendment to a major CNS collaboration. The read-through is that Lilly is still willing to fund tau-pathway optionality alongside amyloid and broader neurodegeneration work, while AC Immune receives near-term non-dilutive cash and keeps exposure to a large milestone/royalty stack.

A clean read-through that Biogen is still willing to pay for enabling nucleic-acid platforms, not just named assets — useful context for how CNS-heavy buyers are sourcing next-wave genetic medicines optionality.

Smart regional monetisation around a mutation-defined oncology program: Frontier keeps Greater China while offloading ex-China development spend to a strategic partner, preserving upside if the p53 Y220C thesis translates clinically.

Another sizeable platform-driven antibody discovery pact, reinforcing that big pharma is still willing to pay meaningful downstream economics for differentiated target-to-antibody engines even before named clinical assets emerge.

Repeat-business validation for Insilico's AI platform from one of the most aggressive pharma buyers in external innovation. The size of the package suggests Lilly sees AI not just as a workflow tool, but as a scalable source of licensable oral assets.

Another sizeable immunology deal for a differentiated multispecific, showing that large buyers will still pay meaningful upfronts for early but mechanistically distinct autoimmune assets.

A classic "big pharma exits, specialist commercial player takes over" transaction, with real cash for a late-stage hepatology asset close to the regulatory finish line.

One of the most significant March BD&L deals: a China-origin commercial asset with a full global rights transfer and no Greater China carve-out. A strategic fit for Sanofi's transplant franchise alongside Rezurock.

Another "China-origin immune engager to global pharma" deal, but in autoimmune disease rather than oncology, with meaningful upfront economics for a differentiated masked/B-cell depletion concept.

One more datapoint that buyers still want differentiated oral immunology mechanisms, even at preclinical stage, if the biology looks first-in-class enough.

Another China-origin oligo deal with real though not giant upfronts — and a sign GSK wants more immunology and kidney shots via RNAi.

A large-ticket oncology deal around a masked T-cell engager with real cost-sharing and U.S. economics retention — not just a simple regional out-license. A strong signal that differentiated TCEs can still command major strategic capital.

Another big-pharma bet on macrocycles as a route to hard-to-drug targets, this time in cardiovascular rather than the usual oncology-heavy mix.

A neat rights-split around a late-stage IL-6 asset: CSL keeps the core renal-cardiovascular angle while Lilly gets optionality to widen the label.

Big milestone torque on a platform-originated MASH expansion — another "China RNAi → global build" template with a meaningful upfront, and a logical portfolio-broadening move for the MASH commercial leader.

Another "ADC platform option → exercise" datapoint — validates AraLinQ and keeps Japan-based buyers active in next-gen ADC technology.

A clean "explore → option-to-license" structure in a resurging modality (recombinant polyclonal IgG) with CSL as a natural strategic buyer.

Another "AI platform + big-pharma pipeline" deal with real headline economics — good sentiment marker for AI-enabled BD&L.

Another "China discovery + global scale" template — big upfront with milestone torque, and a clear division of labour through Phase 2 in China before ex-Greater China execution by Lilly.

A "Japan commercial + local MAH" structure for a de-risked IO asset — modest milestones but attractive royalty profile if uptake lands.

Early "molecular glue" exposure in a clear unmet-need niche (TKI-resistant GIST). Royalty callout suggests meaningful ex-Japan economic participation despite compact economics disclosure.

Roche/Genentech keeps leaning back into RNA — big upfront for an undisclosed program implies conviction in platform chemistry and delivery, with the classic "biotech does early, pharma scales" handoff.

Modest headline value but immediate non-dilutive cash and full global responsibility shift to the partner — if the PDE4 tolerability story holds, the royalty participation has meaningful optionality.

One of the biggest obesity BD packages yet — big upfront and portfolio scope signals "speed + breadth" over single-asset risk. Keeps China rights local while AZ builds global obesity footprint.

A clean "partner commercialisation" structure — Moderna keeps platform focus and de-risks go-to-market, while Recordati expands its rare disease franchise with a late-stage mRNA shot on goal.

Another China-to-West pipeline build: oral immunology differentiation (miR-124 axis) + Formation's "asset-in-Kenmare" structure suggests fast execution toward first-in-human while keeping economics milestone-weighted.

Clear appetite for "immune decoding → precision tolerance" rather than broad immunosuppression. Milestones-heavy economics fit discovery risk while keeping meaningful upside if Lilly's immunology machine delivers.

Yet another bet that next-gen editing beyond standard nuclease paradigms can deliver safer, more precise in vivo outcomes. Lilly is clearly stacking genetic medicine options in hearing and beyond.

AI discovery keeps getting "real money" partner validation — but the structure (milestones + royalties, no disclosed upfront) is a reminder that proof still comes in the clinic.

TL1A is already a crowded hot axis — pairing TL1A with IL-23p19 is a swing at higher efficacy. Meaningful preclinical upfront suggests Boehringer wants a differentiated shot versus mono-pathway competitors.

Classic "platform + antigen" bet: BMS takes the expensive late-stage risk after IND, while Janux keeps upside via milestones and royalties — structure reflects early-stage uncertainty but strong strategic validation.

Rare big-pharma validation of an external adjuvant platform: non-exclusive structure and supply obligation keep Pfizer flexible while giving Novavax recurring upside if Pfizer ships products with Matrix-M.

Clean regional commercialisation expansion: Eisai gets a near-commercial oncology asset for its footprint, while Nuvation keeps U.S. upside — structure signals "execution + geography" rather than core R&D risk.

A non-standard but economically large oncology licensing structure around a Phase 3-ready oral immunotherapy. It is less clean than a big-pharma license, but worth tracking because the proposed headline economics are large relative to OSR/Vaximm and highlight ongoing appetite for structured, finance-led licensing routes around late-stage oncology assets.

Another major "China-to-global" land grab in PD-1/VEGF — big upfront signals confidence and creates optionality for AbbVie combo regimens (especially with ADCs) while keeping Greater China with the originator.

AD BD is shifting from "just antibodies" to delivery and biology differentiation — shuttle tech is the real kicker here. Milestones-heavy economics fit early risk while keeping Novartis in the driver's seat globally.

A useful obesity BD&L datapoint beyond injectables: Lilly is still adding external shots on goal around oral metabolic mechanisms despite already leading the incretin market. The structure is classic discovery-stage risk sharing — modest near-term cash relative to a large milestone stack.

A sizeable early-2026 autoimmune platform deal that combines Sanofi's immunology appetite with Earendil's AI-enabled bispecific discovery engine. The economics are heavily back-ended, but the large upfront / near-term payment package makes it one of the more material discovery-stage BD&L transactions at the start of the year.

Another China-to-global oncology license around a checkpoint bispecific, and a useful comparator to AbbVie's larger RemeGen PD-1/VEGF deal later in January. It reinforces AbbVie's 2026 appetite for China-origin IO assets with differentiated bispecific biology.